The EU's CHMP has recommended approval of Roche/Genentech Inc.'s anti-PD-L1 product Tecentriq (atezolizumab) for use in lung cancer as well as in second-line bladder cancer, despite its recent disappointment in the IMvigor211 study.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?